Verily

Verily is looking forward to this year’s AHIP event, June 11-13 in Las Vegas, to connect on what’s new in healthcare with health plan leaders, including our upcoming news... Join us at booth #1232 to hear Verily’s latest planned addition to our care portfolio, as we deepen our commitment to supporting members living with chronic conditions. https://veri.ly/4bApUmD #AHIP2024 #PrecisionHealth

Depression is a leading cause of disability worldwide, with more than one in six U.S. adults reporting they are depressed or receiving treatment for depression.* By understanding their experiences across time and in a real-world setting we can pave the way for more effective treatments. Learn about the ‘My Mental Health Journey’ longitudinal registry study that we worked with Otsuka Pharmaceutical Companies (U.S.) to launch. The aim is to advance research in depression and mental health to support the development of more precise treatment options: https://veri.ly/3UXmRhc *https://veri.ly/3V5IfB7 #MentalHealthAwarenessMonth #MentalHealth #PrecisionHealth

Psychiatric trials face the lowest success rates among major therapeutic areas across all clinical trial phases. Only 6.2% of compounds entering psychiatric clinical development get regulatory approval, which leads to lower investment in new treatments. Verily experts and collaborators lay out how digital measures, such as those captured through a wearable or smartphone device, can help address three central challenges in psychiatric trials: ➡️ Psychiatric heterogeneity - by differentiating between patient subtypes via predictive digital biomarkers of treatment response ➡️ Endpoint subjectivity - by providing more objective measures of patient functioning that are related to meaningful aspects of health and that are sensitive to treatment response ➡️ High placebo response rates - by identifying patients that are less likely to respond to placebo via predictive digital biomarkers of placebo response Overall, our team discusses the potential for using digital biomarkers to de-risk psychiatry trials and accelerate treatments and cures for mental health conditions. Read more in Nature Portfolio Neuropsychopharmacology - Digital Psychiatry and Neuroscience: https://lnkd.in/gzAjPDg4 We are proud to advance this space with the use of Verily Study Watch to capture digital measures in clinical trials across a variety of therapeutic areas, including psychiatry. #DigitalBiomarkers #MentalHealth #ClinicalTrials #psychiatry

Sean Horgan with Verily Vets and I set this Memorial Day Remembrance Table in our Verily Boston office. "This table is set in memory of those that served our country and paid the ultimate sacrifice. Each item is a symbol that helps us remember their courage, their dedication, and the profound impact their loss has had on their families and communities. We will remember them always. The table is round, to show our everlasting concern for those we lost. The cloth is white, symbolizing their pure intentions when answering the call to serve. The single red rose symbolizes the blood shed. A slice of lemon reminds us of their bitter fate and the harsh realities of war, which impacts so many innocent people. A pinch of salt symbolizes the tears of grief shed by loved ones in mourning. The lighted candle reflects our memory of the fallen and hope for the return of the missing in action and prisoners of war. The glass is inverted, symbolizing their inability to share a toast. The chair is empty, the seat that remains unclaimed at the table."

We’re wrapping up a month of activities to celebrate Asian Pacific American Heritage Month. Thank you to our Hyphen ERG for bringing Veeps together and hosting dance workshops, game nights, and an internal talk with Asian leaders at Verily. So fun, inspiring and educational 👏 #AAPIHeritageMonth #AAPIMonth #LifeAtVerily

The study detailing our work with WastewaterSCAN to detect H5 in wastewater has been published in ACS Publications. Verily Principal Scientist Bradley White and team quickly developed an assay to detect H5 in wastewater samples in response to uncharacteristic spikes in Influenza A found in wastewater plants in Texas, near H5N1 outbreaks. Tests on wastewater samples revealed the presence of H5 in samples collected shortly before and during the reported cases. The study hypothesizes that H5 is entering municipal wastewater systems through effluent discharged by dairy cattle milk processing plants, which are located within the sewersheds. Our work suggests that wastewater testing can serve as a critical public health monitoring tool by detecting new and emerging pathogens and providing insights. Read more in the paper co-authored by researchers from Rollins School of Public Health at Emory University, Verily and Stanford University School of Engineering: https://lnkd.in/ezGYXfkZ #H5N1 #BirdFlu #AviaryInfluenza #PublicHealth #PrecisionHealth 

Our Chairman and CEO Stephen Gillett discussed Verily’s mission, products and commitment to advancing precision health with Newsweek Investment Reports as part of the annual “New Era of Life Sciences 2024 Report.” “Looking ahead, the integration of advanced AI capabilities into healthcare stands out as a significant opportunity for Verily.” Read more: https://bit.ly/3VdKK5D #HealthInnovation #PrecisionHealth

"There needs to be a culture of privacy and security, especially in healthcare," said Stephen Gillett, our Chairman and CEO, while on stage at Fortune Brainstorm Health with Bob Segert, Andrea Downing and moderator Andrew Nusca. Stephen also discussed lessons learned from the Change Healthcare breach, including the opportunities for partnerships between the public and private sectors. "Public private partnership will take average or below average security and make it good or great but don't try to do it all yourself." Watch the recording: https://veri.ly/3QTAs85 #FortuneHealth #cybersecurity #HealthData